
    
      This is a multi-center, randomized, open-label, Phase 3 study comparing Pexa Vec followed by
      sorafenib versus sorafenib in patients with advanced HCC without prior systemic therapy.

      A total of 459 patients were randomly assigned to 2 treatment arms- 234 patients in the
      Pexa-Vec followed by sorafenib treatment group and 225 patients in the sorafenib only
      treatment group.
    
  